MARKET

ACER

ACER

Acer Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.280
-0.050
-1.50%
Closed 16:49 11/18 EST
OPEN
3.280
PREV CLOSE
3.330
HIGH
3.325
LOW
3.170
VOLUME
16.68K
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
1.871
MARKET CAP
33.11M
P/E (TTM)
-1.0099
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACER and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACER News

  • Acer Therapeutics EPS beats by $0.05
  • seekingalpha.5d ago
  • Acer Therapeutics Q3 EPS $(0.52) Down From $(0.43) YoY
  • Benzinga.5d ago
  • Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
  • GlobeNewswire.5d ago
  • Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders
  • GlobeNewswire.10/28 21:01

More

Industry

Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
+0.13%

Hot Stocks

Name
Price
%Change

About ACER

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
More

Webull offers Acer Therapeutics Inc (ACER) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.